Alpha 2.0
Login Register
» Authors » Franco Felizarta

Franco Felizarta

Explore the profile of Franco Felizarta including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 1267
Followers 0
Related Specialties
Infectious Diseases
Gastroenterology
General Medicine
Top 10 Co-Authors
Federico J Mensa
Fred Poordad
Chih-Wei Lin
Jens Kort
Armen Asatryan
Humberto Aguilar
Tarek Hassanein
Stanley Wang
Mark S Sulkowski
Edwin DeJesus
Published In
Hepatology
J Hepatol
Clin Infect Dis
J Acquir Immune Defic Syndr
Antimicrob Agents Chemother
Affiliations
Soon will be listed here.
Recent Articles
1.
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With Human Immunodeficiency Virus Type 1: A Substudy of the Phase 3b ATLAS-2M Study
Ford S, Felizarta F, Han K, Wang K, Crauwels H, Dari A, et al.
Clin Infect Dis . 2025 Jan; PMID: 39878031
Background: Cabotegravir + rilpivirine (CAB + RPV) administered via intramuscular gluteal injections is the first complete long-acting regimen for maintaining human immunodeficiency virus type 1 (HIV-1) virologic suppression. We present...
2.
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Schneider S, Blick G, Burke C, Ward D, Benson P, Felizarta F, et al.
Infect Dis Ther . 2024 Apr; 13(4):891-906. PMID: 38570443
Introduction: Dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) are fixed-dose, complete, single-tablet, two-drug regimens (2DRs) indicated for HIV-1. DTG/3TC is approved for antiretroviral therapy (ART)-naive people with HIV-1 and virologically suppressed individuals...
3.
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial
Karver T, Pascual-Bernaldez M, Berni A, Hnoosh A, Castagna A, Messiaen P, et al.
AIDS Patient Care STDS . 2023 Jan; 37(1):53-59. PMID: 36626155
Cabotegravir and rilpivirine long-acting (LA) antiretroviral therapy (ART) demonstrated similar safety and efficacy in maintaining viral suppression among participants switching from daily oral to LA ART in the Extension Phase...
4.
Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study
Poordad F, Felizarta F, Yao B, Overcash J, Hassanein T, Agarwal K, et al.
Liver Int . 2022 Feb; 42(6):1278-1286. PMID: 35220658
Background And Aims: This study aimed to determine durability of sustained virologic response (SVR) in hepatitis C virus-infected participants treated with glecaprevir- and/or pibrentasvir-containing regimens. Methods: M13-576, a rollover study,...
5.
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
Spinner C, Felizarta F, Rizzardini G, Philibert P, Mitha E, Domingo P, et al.
Clin Infect Dis . 2022 Jan; 75(5):786-794. PMID: 34996113
Background: GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy. Methods: This phase IIa double-blind (sponsor-unblinded), randomized, placebo-controlled, adaptive study...
6.
Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials
Poordad F, Castro R, Asatryan A, Aguilar H, Cacoub P, Dieterich D, et al.
J Viral Hepat . 2020 Jan; 27(5):497-504. PMID: 31954087
The 3-DAA regimen consisting of ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) has shown high sustained virologic response rates (~95%) in phase 3 clinical trials including >2300 HCV...
7.
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
Letendre S, Mills A, Hagins D, Swindells S, Felizarta F, Devente J, et al.
J Antimicrob Chemother . 2019 Dec; 75(3):648-655. PMID: 31873746
Background: Long-acting (LA) formulations of cabotegravir, an HIV integrase inhibitor, and rilpivirine, an NNRTI, are in development as monthly or 2 monthly intramuscular (IM) injections for maintenance of virological suppression....
8.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection
DeJesus E, Harward S, Jewell R, Johnson M, Dumont E, Wilches V, et al.
Clin Infect Dis . 2019 Nov; 71(5):1255-1262. PMID: 31769793
Background: GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer. Methods: The phase 2a, proof-of-concept study was...
9.
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial
Brown Jr R, Buti M, Rodrigues L, Chulanov V, Chuang W, Aguilar H, et al.
J Hepatol . 2019 Nov; 72(3):441-449. PMID: 31682879
Background & Aims: Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1-6 in treatment-naïve patients without cirrhosis. We evaluated...
10.
Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
Grebely J, Dore G, Alami N, Conway B, Dillon J, Gschwantler M, et al.
Int J Drug Policy . 2019 Feb; 66:73-79. PMID: 30735896
Background: International guidelines recommend treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID), including those on opioid substitution therapy (OST). The pangenotypic combination of glecaprevir and...